Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

A method for alleviating chronic fatigue syndrome with the administration of antiviral agents. Based on clinical tests, chronic fatigue syndrome is a persistent herpes virus infection including incomplete virus multiplication and thus administration of antiviral agents are shown to alleviate the symptoms associated with the disorder. Based on therapeutic trials, patients receiving the recommended antiviral treatment, have experienced significant reduction or elimination of the symptoms associated with chronic fatigue syndrome. A method of diagnosis of the chronic fatigue syndrome is further disclosed.

Inventor: A. Martin Lerner
Primary Examiner: Russell Travers
Attorney: Brooks & Kushman P.C.
Current U.S. Classification: 514/263.38; 514/49
International Classification: A61K/31505; A61K/3170

View patent at USPTO
Search USPTO Assignment Database
Download USPTO Public PAIR data

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US4544634Oct 14, 1982Oct 1, 1985Burroughs Wellcome Co.Method of producing acyclovir
US4695570Mar 15, 1985Sep 22, 1987Burroughs Wellcome Co.Antiviral compound use
US4897394Jan 29, 1987Jan 30, 1990Burroughs Wellcome CO.Antiviral combinations
US4957924Aug 4, 1988Sep 18, 1990Burroughs Wellcome Co.Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof
US5055296Aug 4, 1988Oct 8, 1991Method of treating chronic fatigue syndrome
US5061708Nov 21, 1989Oct 29, 1991Burroughs Wellcome Co.Therapeutic guanine esters
US5079252Jul 13, 1989Jan 7, 1992Buroughs Welcome Co.Therapeutic compounds
US5189022May 8, 1991Feb 23, 1993The United States of America as represented by the Secretary of Health and Human ServicesComposition for the treatment of chronic fatigue syndrome
US5206008Aug 2, 1991Apr 27, 1993Virginia Commonwealth UniversityEnhancement of immune response
US5213106Mar 25, 1991May 25, 1993Diagnosing and treating chronic fatigue syndrome by electrocardiographic monitoring of T-waves
US5267570Dec 30, 1992Dec 7, 1993Method of diagnosing and treating chronic fatigue syndrome
US5312817May 14, 1992May 17, 1994Treatment of fatigue syndrome
US5357968Aug 31, 1992Oct 25, 1994Diagnosing and treating subacute myocarditis
US5405850Oct 29, 1992Apr 11, 1995Burroughs Wellcome Co.Antiviral compositions consisting of acyclovir and a 2-acetyl pyridine derivative
US5426028Nov 4, 1991Jun 20, 1995Rush-Presbyterian-St. Lukes Medical Center
The Regents of The University of California		Screening method for chronic immune dysfunction syndrome
US5461042Jan 3, 1994Oct 24, 1995Regulation of the immune system
US5464020Apr 4, 1994Nov 7, 1995Diagnosing and treating subacute cardiac dysfunction
US5491150Jan 27, 1994Feb 13, 1996Ajinomoto Co., Inc.Supplementary therpeutic agents for the treatment of immunodeficiency syndrome
US5538856Mar 7, 1995Jul 23, 1996The Regents of the University of CaliforniaScreening kit and method for diagnosing chronic immune dysfunction syndrome
US5545550May 27, 1994Aug 13, 1996Medical College of Wisconsin, Inc.Human virus associated with chronic fatigue immune deficiency syndrome and assay therefore
US5545670Jun 8, 1994Aug 13, 1996Composition and method for the treatment of chronic fatigue syndrome
US5872123Feb 18, 1997Feb 16, 1999Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6258818Oct 23, 1998Jul 10, 2001Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome

Claims

1. A method of diagnosing and alleviating the symptoms of chronic fatigue syndrome in a patient exhibiting symptoms associated with chronic fatigue syndrome, comprising:

evaluating the patient for serologic evidence of EBV and HCMV, further comprising:
obtaining serum from the patient;
measuring the level of EBV IgM antibodies to the VCA in the serum;
measuring the level of EBV antibodies to the total EA in the serum;
measuring the level of HCMV IgM antibodies in the serum by measuring antigens p52 and CM2 with the use of a light scattering technique;
measuring the level of HCMV IgG antibodies in the serum by measuring antigens p52 and CM2 with the use of a light scattering technique;
monitoring the patient for T-wave abnormalities;
classifying EBV as the cause of the chronic fatigue syndrome when the measurements show any one of the following: 1) an elevated level of IgM antibodies to the VCA for EBV; and 2) presence of total EA antibodies for EBV, in combination with the absence of IgM antibodies for HCMV and a low level of IgG antibodies for HCMV;
classifying HCMV as the cause of the chronic fatigue syndrome when the measurements show any one of the following: 1) an elevated level of IgM antibodies for HCMV; and 2) an elevated level of IgG antibodies for HCMV, in combination with a low level of IgM antibodies to the VCA for EBV, and the absence of total EA antibodies for EBV;
classifying a combination of EBV and HCMV as the cause of the chronic fatigue syndrome when the measurements show any one of the following: 1) an elevated level of IgM antibodies to the VCA for EBV; and 2) the presence of total EA antibodies for EBV, in combination with any of the following: 1) an elevated level of IgM antibodies for HCMV; and 2) an elevated level of IgG antibodies for HCMV;
administering to the patient a therapeutically effective amount of one or more pharmaceutically acceptable antiviral agents suitable for EBV, HCMV or a combination thereof, wherein the one or more antiviral agents are selected from the group consisting of valganciclovir, and pharmaceutically acceptable derivatives and mixtures thereof; and
conducting supplemental tests to check for recurrent chronic fatigue syndrome to determine an appropriate treatment period for the patient to achieve continued alleviation of the symptoms of chronic fatigue syndrome.

2. The method of claim 1, wherein the patient is administered 0.1 to 50 milligrams of valganciclovir per kilogram of body weight of the patient over six hours.

Drawings